Table A29:
Net Budget Impact of Funding Continuous Glucose Monitoring in Ontario—Scenario 3, Conservative Projection of a 20% Annual Increase, Device Cost Reduction by 30%, 20%, and 10%
| Intervention | Total Budget Impact | ||||
|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
| CGM Device Cost | |||||
| CGM | $24,229,379 | $29,075,255 | $34,890,306 | $41,868,368 | $50,242,041 |
| SMBG | $10,565,739 | $12,678,887 | $15,214,665 | $18,257,598 | $21,909,117 |
| NBI | $13,663,640 | $16,396,368 | $19,675,642 | $23,610,770 | $28,332,924 |
| CMG Device Cost + 75% Funding of Sensor Costs | |||||
| CGM | $21,962,668 | $26,355,201 | $31,626,241 | $37,951,490 | $45,541,787 |
| SMBG | $10,565,739 | $12,678,887 | $15,214,665 | $18,257,598 | $21,909,117 |
| NBI | $11,396,928 | $13,676,314 | $16,411,577 | $19,693,892 | $23,632,670 |
| CGM Device Cost Reduction of 30% | |||||
| CGM | $16,960,566 | $20,352,679 | $24,423,214 | $29,307,857 | $35,169,429 |
| SMBG | $10,565,739 | $12,678,887 | $15,214,665 | $18,257,598 | $21,909,117 |
| NBI | $6,394,826 | $7,673,791 | $9,208,550 | $11,050,260 | $13,260,312 |
| CGM Device Cost Reduction of 20% | |||||
| CGM | $19,383,504 | $23,260,204 | $27,912,245 | $33,494,694 | $40,193,633 |
| SMBG | $10,565,739 | $12,678,887 | $15,214,665 | $18,257,598 | $21,909,117 |
| NBI | $8,817,764 | $10,581,317 | $12,697,580 | $15,237,096 | $18,284,516 |
| CGM Device Cost Reduction of 10% | |||||
| CGM | $21,806,441 | $26,167,730 | $31,401,276 | $37,681,531 | $45,217,837 |
| SMBG | $10,565,739 | $12,678,887 | $15,214,665 | $18,257,598 | $21,909,117 |
| NBI | $11,240,702 | $13,488,843 | $16,186,611 | $19,423,933 | $23,308,720 |
Abbreviations: CGM, continuous glucose monitoring; NBI, net budget impact; SMBG, self-monitoring of blood glucose.